...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
【24h】

Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity

机译:通过两种不同抗体靶向的脂质体:测定,B细胞结合和细胞毒性

获取原文
获取原文并翻译 | 示例

摘要

The selective toxicity of anticancer drugs can be improved with the use of antibody-targeted liposomes. We hypothesize that liposomes targeted via antibodies against two or more receptor populations will increase the apparent receptor density on the target cells, resulting in improved therapeutic affects. A fluorescent assay was developed, using the fluorophores Alexa Fluor (R) 350 and 532 to label monoclonal antibodies (mAb), and used to quantitate two different mAb populations coupled to the same liposome surface to within +/- 10% of the values obtained with radiolabeled antibody (1251) tracers. The binding and uptake of targeted liposomes by B lymphoma (Namalwa) cells were examined for either individual populations of alpha CD19-targeted or alpha CD20-targeted liposomes, mixed populations (1: 1) of alpha CD19-targeted liposomes plus aCD20-targeted liposomes, and dual-targeted liposomes, i.e., equal amount of both alpha CD19 and alpha CD20 on the same liposomes. At similar antibody densities, the binding and uptake of the dual-targeted liposomes were greater than that of either individually targeted liposomes alone, and showed additivity. At the same total lipid and antibody densities, 1:1 mixtures of individually targeted liposomes gave similar results to dual-targeted liposomes. Cytotoxicity was also improved, with DXR-loaded dual-targeted liposomes appearing to have higher cytotoxicity than 1:1 mixtures of individually targeted liposomes. (c) 2005 Elsevier B.V All rights reserved.
机译:抗癌药的选择性毒性可以通过使用靶向抗体的脂质体来改善。我们假设通过针对两个或多个受体群体的抗体靶向的脂质体将增加靶细胞上的表观受体密度,从而改善治疗效果。开发了一种荧光测定法,使用荧光团Alexa Fluor(R)350和532标记单克隆抗体(mAb),并用于将偶联到同一脂质体表面的两个不同mAb群体定量到所获得值的+/- 10%以内用放射性标记的抗体(1251)示踪剂。检查了B淋巴瘤(Namalwa)细胞对靶向脂质体的结合和摄取情况,以研究单个αCD19靶向或αCD20靶向脂质体,αCD19靶向脂质体的混合人群(1:1)和aCD20靶向脂质体以及双重靶向脂质体,即在相同脂质体上相等量的αCD19和αCD20。在相似的抗体密度下,双重靶向脂质体的结合和摄取均大于单独的任何单一靶向脂质体的结合和摄取,并显示出可加性。在相同的总脂质和抗体密度下,单独靶向脂质体的1:1混合物与双重靶向脂质体的结果相似。细胞毒性也得到了改善,与DXR双重靶向脂质体相比,单个靶向脂质体的1:1混合物似乎具有更高的细胞毒性。 (c)2005 Elsevier B.V保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号